Researchers reported negative results from the first repeated-dose study of a dopamine-1 receptor (D1R) agonist for treating cognitive and negative symptoms of schizophrenia.Based on earlier preclinical research suggesting …

Visit site: 

Disproving hypothesis clears path for research for new treatment …